Quick status check on Novo, Lilly, and rivals after ADA 2025 – just ahead of Q2 earnings. Introduction Novo Nordisk and Eli Lilly will release their Q2 results on 6 and 7 August.ADA 2025, which wrapped at the end of June, delivered a blitz of new obesity data. Below is a look at every major …
Continue reading “The Obesity Drug Chessboard after ADA2025 with Q2 Earnings in Play ♟️”
Riding the First Wave: Wegovy® and Zepbound® 🏄 GLP-1 weight loss drugs Wegovy® (semaglutide) and Zepbound® (tirzepatide) from Novo Nordisk and Eli Lilly hit markets like a tsunami, when they were approved in June 2021 and November 2023, due to their unprecedented weight-loss efficacy 🌊 The next waves might not be as colossal, but they …
Continue reading “The Next Wave of Obesity Drugs: Opportunities and Risks for Investors 🌊”
The FDA on May 13th approved the dual GIP-GLP1-agonist Mounjaro® (tirzepatide) from Eli Lilly for diabetes following the completion of the SURPASS studies (e.g. SURPASS-2 NCT03987919). Mounjaro® is administered as a weekly injection just like the GLP1-agonist Ozempic® (semaglutide) from Novo Nordisk for diabetes. The table below summarizes products from Eli Lilly and Novo Nordisk …
Novo Nordisk continues to succeed in the GLP-1 space with semaglutide (Ozempic®, Rybelsus® and Wegovy®). Highlights of the quarter include initiation of phase 3a trials with oral semaglutide in obesity and ziltivekimab in cardiovascular disease. Novo Nordisk now has late stage clinical trials in all of their therapy areas. Ozempic® continues to be one of …
Continue reading “Novo Nordisk 2021Q3 – Wegovy® bottlenecks”
Novo Nordisk sales and operating profit grew at 12% and 9%, respectively, at constant exchange rates. The FDA approved the once-weekly injectable anti-obesity drug Wegovy® (semaglutide) on June 4th. The figures below summarize the global sales for Novo Nordisk by geography, by drug and by drug class. All geographic markets have experienced growth, but Victoza® …
Continue reading “Novo Nordisk Q2 saw approval of Wegovy® and continued growth of Ozempic® sales”
Novo Nordisk has gained market share in diabetes (29.2%), GLP-1 (49.9%) and insulin (44.5%). The gain in market share has happened with a change in market value in the US as a backdrop; i.e. GLP-1 up and insulin down. As a consequence approximately 70% of sales in the US did not exist 5 years ago. …
Novo Nordisk has reported their 2nd quarter results. Financials For the 2nd quarter sales were DKKm 30,006 (-0%), gross profit was DKKm 25,234 and operating income was DKKm 13,838 (+3%). In the US GLP1 for diabetes increased by 19%, whereas insulin decreased by 34%. CEO Lars Fruergaard Jørgensen “The U.S. sales decline was driven by …
Continue reading “Novo Nordisk grows GLP-1 market share in Q2 in the US with Ozempic® and Rybelsus®”
Novo Nordisk is with the exception of the postponement of new clinical trials mostly unaffected by COVID-19. Sales in Q1 were however positively affected by stock piling of insulin. Growth continues to be spearheaded by Ozempic®, whereas Victoza® and Levemir® in the US continue to lead the decline. Rybelsus® revenue totaled DKKb 229 in the …
Continue reading “Novo Nordisk mostly unaffected by COVID-19 in Q1”
Anti-diabetic oral GLP1 drug Rybelsus® (semaglutide) received FDA approval on September 20th and 70%-80% of patients are not coming from other injectables. GLP1 drug segment is growing led by the weekly injectable anti-diabetic drug Ozempic® (semaglutide) approved for CV risk reduction in the US. Revenue in US diabetes segment is flat due to declining revenue …
Novo Nordisk and Eli Lilly have both reported their Q3 results. Below are some of the headlines related to their diabetes business. Novo Nordisk OG2023SC, an oral GLP-1 analogue, has been discontinued based on encouraging results for an enhanced oral semaglutide formulation. US FDA decision on cardiovascular indication for Rybelsus® is expected in the first …
